EN DE
Watch Next Biomedical Co.,Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Next Biomedical Co.,Ltd (389650) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Next Biomedical Co.,Ltd stock KRW 18,952, price KRW 23,800, that is 20.4% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

NB Next Biomedical Co.,Ltd logo Thin data Nov 16, 2026

Next Biomedical Co.,Ltd

389650 · KQ

Expensive (fair value 20% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Ranks above peers (7/10) 
Revenue last quarter +24% vs. a year ago. 
Quality 42/100 
Expensive Growth (revenue 3y +80.6 %/yr in KRW) 
Thin margins · 1.3% net margin (TTM) 
Fair value 18,952 KRW · Overvalued 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 18/100
Thin data 
Estimate
Watch Next Biomedical Co.,Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

98,000 KRW 23,700 KRW Fair Value 18,952 KRW Aug 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

27‑month range 23,700 KRW – 98,000 KRW · fair‑value band 14,214 KRW – 23,689 KRW · the 23,800 KRW price screens above the 18,952 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Next Biomedical Co. in your weekly email

Every Wednesday you see whether Next Biomedical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization.

Show moreShow less

The company was founded in 2014 and is based in Incheon, South Korea.

Stock analysis

Next Biomedical Co.,Ltd (389650) currently trades at 23,800 KRW, while our estimate is 18,952 KRW, 20% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 14,214 KRW (bear) to 23,689 KRW (bull), the price of 23,800 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Next Biomedical Co.,Ltd reported revenue of 16.5B KRW in FY2025 versus 2.3B KRW in FY2021, a compound +64.2%/yr. Reported net income was −311M KRW in FY2025.

Key figures

Market cap 197B KRW (≈ $147M) Micro · P/S ratio 12.6 · EPS (TTM) 28.10 KRW · Net margin 1.3% · Return on equity 0.5% · Return on assets (EBIT) −11.4% (5-year average) · Operating margin −21.0% · Revenue (TTM) 17.8B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).

What moves the price

The share trades about 76% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −20%, 389650 screens richer than that median.

Fair Value

Bear 14,214 KRW Fair Value 18,952 KRW Bull 23,689 KRW
Price 23,800 KRW · Downside -20.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 17
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 12
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 2
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 1
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+72.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+80.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−307.4% (2021) → −4.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

389650 screens overvalued: fair value 20% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Next Biomedical Co.,Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 42 · Above median
Fair Value upside −20.4% · Above median
Profitability
Return on equity (12 months) 0.5% · Above median
Return on assets −0.5% · Top 25%
Net margin (12 months) 1.3% · Above median
Operating margin (12 months) −21.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 24.3% · Above median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.10× · Pricier than median
P/S (12 months) 11.07× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)6 · sector 1
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)2 · sector 0
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 389650
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 389650
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs 389650
argenx SE ARGX $950.95 $908.40 −4% vs 389650
CSL Limited CSL A$199.55 A$186.49 −7% vs 389650
Moderna, Inc MRNA $215.27 $135.64 −37% vs 389650
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs 389650
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 389650
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs 389650
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 389650

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Next Biomedical Co.,Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Next Biomedical Co.,Ltd Fair Value". https://www.fairvalue-calculator.com/stock/389650

Frequently asked questions

Is Next Biomedical Co.,Ltd (389650) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 18,952 KRW versus a price of 23,800 KRW, about 20% lower (overvalued).
What is the fair value of 389650?
Our estimate for Next Biomedical Co.,Ltd is 18,952 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 23,800 KRW.
What is the quality score of 389650?
Next Biomedical Co.,Ltd has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Next Biomedical Co.,Ltd (389650)?
Our calculated price target is the estimate of 18,952 KRW (as of Nov 16, 2026). Cautious scenario 14,214 KRW, optimistic scenario 23,689 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Next Biomedical Co.,Ltd stock forecast for 2026?
Our estimate puts fair value at 18,952 KRW, about 20% lower versus a price of 23,800 KRW (overvalued). Cautious scenario 14,214 KRW, optimistic scenario 23,689 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Next Biomedical Co.,Ltd (389650)?
Next Biomedical Co.,Ltd reported trailing-twelve-month revenue of about 17.8B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Next Biomedical Co.,Ltd (389650)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Next Biomedical Co.,Ltd it is 18,952 KRW per share (as of Nov 16, 2026), against a price of 23,800 KRW.
Is Next Biomedical Co.,Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 389650 trades above its calculated fair value: price 23,800 KRW, fair value 18,952 KRW, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 389650?
No. The price is what the market pays today (23,800 KRW); the fair value is what the company's own numbers justify (18,952 KRW). For Next Biomedical Co.,Ltd the two are 4,848 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Next Biomedical Co.,Ltd worth?
The market values Next Biomedical Co.,Ltd at about 197B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 23,800 KRW; our models calculate a fair value of 18,952 KRW per share.
What do the bullish and bearish scenarios say about 389650?
Our models span a range for Next Biomedical Co.,Ltd: cautious scenario 14,214 KRW, base 18,952 KRW, optimistic 23,689 KRW per share (as of Nov 16, 2026, price 23,800 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Next Biomedical Co.,Ltd (389650)?
Balance-sheet figures for Next Biomedical Co.,Ltd (as of Nov 16, 2026): return on equity 0.5%, debt of 0.02 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 389650 from its 52-week high?
Next Biomedical Co.,Ltd trades at 23,800 KRW, about 76% below its 52-week high of 98,000 KRW and at the low of 23,800 KRW (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 18,952 KRW is for.
Which stocks are comparable to Next Biomedical Co.,Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Next Biomedical Co.,Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price 23,800 KRW, calculated fair value 18,952 KRW (−20%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Next Biomedical Co.,Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Next Biomedical Co.,Ltd (389650)?
The closing price on Nov 16, 2026 was 23,800 KRW. Our estimate is 18,952 KRW, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Next Biomedical Co.,Ltd right now?
Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Next Biomedical Co.,Ltd

How large is the market capitalisation of Next Biomedical Co.,Ltd (389650)?
The market capitalisation of Next Biomedical Co.,Ltd is 197B KRW (≈ $147M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Next Biomedical Co.,Ltd (389650)?
The price-to-sales ratio of Next Biomedical Co.,Ltd is 12.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Next Biomedical Co.,Ltd (389650)?
Earnings per share at Next Biomedical Co.,Ltd are 28.10 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Next Biomedical Co.,Ltd (389650)?
The net margin of Next Biomedical Co.,Ltd is 1.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Next Biomedical Co.,Ltd (389650)?
The return on equity (ROE) of Next Biomedical Co.,Ltd is 0.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Next Biomedical Co.,Ltd (389650)?
On an EBIT basis the return on assets of Next Biomedical Co.,Ltd is −11.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Next Biomedical Co.,Ltd (389650)?
The operating margin of Next Biomedical Co.,Ltd is −21.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Next Biomedical Co.,Ltd (389650)?
Revenue at Next Biomedical Co.,Ltd is growing 24.3% versus a year earlier (3y avg +80.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Next Biomedical Co.,Ltd (389650) generate?
The free cash flow of Next Biomedical Co.,Ltd is −1.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Next Biomedical Co.,Ltd (389650) carry?
The net debt of Next Biomedical Co.,Ltd is 814M KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Next Biomedical Co.,Ltd in the live analysis

One click puts Next Biomedical Co.,Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.